Coherus Oncology (CHRS) EBIT Growth (3y) (2016 - 2026)
Powered by 
Analysis
Coherus Oncology (CHRS) EBIT Growth (3y) (2016 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 9.40% |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | -102.00% |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 6.70% |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 8.36% |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 89.72% |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 24.14% |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 44.34% |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | -96.48% |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | - |
| 10 | Coherus Oncology | 209.00 Mn | 103.70 Mn | 10.07 Mn | 2.18% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 2.18% |
| Mar 31, 2026 | 18.89% |
| Dec 31, 2025 | 3.77% |
| Sep 30, 2025 | 18.01% |
| Jun 30, 2025 | -1.10% |
| Mar 31, 2025 | 17.50% |
| Dec 31, 2024 | -4.70% |
| Sep 30, 2024 | -12.64% |
| Jun 30, 2024 | -17.92% |
| Mar 31, 2024 | 26.01% |
| Dec 31, 2023 | -83.66% |
| Sep 30, 2023 | -43.41% |
| Jun 30, 2023 | -36.24% |
| Mar 31, 2023 | -54.08% |
| Dec 31, 2022 | -46.49% |
| Sep 30, 2022 | -52.58% |
| Jun 30, 2022 | -53.27% |
| Mar 31, 2022 | -69.56% |
| Dec 31, 2021 | 13.21% |
| Sep 30, 2021 | 16.82% |